| Nimy Resources Limited (NIM) ORDINARY FULLY PAID |
Materials |
$21 |
Proposed issue of securities - NIM
|
21 May 2025 9:19AM |
$0.105 |
$0.058 |
fallen by
44.76%
|
|
| Nimy Resources Limited (NIM) ORDINARY FULLY PAID |
Materials |
$21 |
Proposed issue of securities - NIM
|
21 May 2025 9:19AM |
$0.105 |
$0.058 |
fallen by
44.76%
|
|
| Platinum Asset Management Limited (PTM) ORDINARY FULLY PAID |
Financials |
$1,556 |
Notification regarding unquoted securities - PTM
|
21 May 2025 9:19AM |
$0.570 |
$0.695 |
risen by
21.93%
|
|
| Nimy Resources Limited (NIM) ORDINARY FULLY PAID |
Materials |
$21 |
Proposed issue of securities - NIM
|
21 May 2025 9:19AM |
$0.105 |
$0.058 |
fallen by
44.76%
|
|
| Nimy Resources Limited (NIM) ORDINARY FULLY PAID |
Materials |
$21 |
$2.75m Placement to advance Gallium JORC Resource Drilling
|
21 May 2025 9:19AM |
$0.105 |
$0.058 |
fallen by
44.76%
|
|
NIM - Price-sensitive ASX Announcement
Full Release
Key Points
- Nimy Resources Limited (NIM) has announced a $2.75 million placement to advance Gallium JORC Resource drilling.
- The placement was oversubscribed, reflecting strong support from institutional and sophisticated investors.
- Funds raised will be used to expedite drilling at the Mons Project, targeting a maiden JORC Resource for Gallium and Nickel.
- The placement price was set at $0.13 per share, with 21,153,846 new shares to be issued.
- Proceeds will also support further exploration activities, metallurgical test work, and working capital requirements.
- The Mons project has demonstrated significant potential for Gallium, an emerging critical mineral, as well as Nickel and other base metals.
- Recent drilling results have highlighted exceptional Gallium grades, positioning Nimy Resources as a potential early mover in Australian Gallium resources.
- The company is focused on delivering resource growth and value creation for shareholders through strategic exploration and development.
- The placement is seen as a key step in unlocking the broader mineral potential of the Mons Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Compumedics Limited (CMP) ORDINARY FULLY PAID |
Health Care |
$73 |
Somfit Pharma Business
|
21 May 2025 9:18AM |
$0.300 |
$0.365 |
risen by
21.67%
|
|
| Verbrec Limited (VBC) ORDINARY FULLY PAID |
Industrials |
$50 |
Verbrec secures over $11m in new contracts
|
21 May 2025 9:17AM |
$0.057 |
$0.170 |
risen by
198.25%
|
|
VBC - Price-sensitive ASX Announcement
Full Release
Key Points
- Verbrec Limited announced securing over $11 million in new contracts.
- Contracts cover energy, infrastructure, and mining sectors in Australia and New Zealand.
- Wins include both new clients and repeat business, indicating customer satisfaction and trust.
- The company emphasizes a diversified order pipeline and a strong market position.
- Verbrec reiterates confidence in meeting FY24 guidance with continued project wins.
- Operational and risk management improvements have contributed to recent success.
- Verbrec aims to further leverage its expertise and relationships amid sector opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Echo IQ Limited (EIQ) ORDINARY FULLY PAID |
Information Technology |
$176 |
Update on Category III CPT Code Application
|
21 May 2025 9:16AM |
$0.240 |
$0.270 |
risen by
12.50%
|
|
EIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Echo IQ Limited sought approval for a Category III CPT code for its EIQ platform from the AMA.
- The application was not approved by the CPT Editorial Panel at this time.
- Echo IQ received feedback from the AMA and plans to address the panel's comments.
- The company will collaborate with clinical partners and advisors to further strengthen its evidence base.
- Echo IQ remains focused on pursuing code approval in the future.
- The EIQ platform uses AI to help detect patients with moderate-to-severe aortic stenosis.
- Continued clinical engagement and data collection are prioritized for broader adoption and reimbursement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mighty Kingdom Limited (MKL) ORDINARY FULLY PAID |
Communication Services |
- |
Consolidation/Split - MKL
|
21 May 2025 9:12AM |
$0.007 |
$0.165 |
risen by
2,257.14%
|
|
| Blue Star Helium Limited (BNL) ORDINARY FULLY PAID |
Energy |
$25 |
State 9 Drilling Spud
|
21 May 2025 9:12AM |
$0.007 |
$0.007 |
fallen by
0%
|
|
BNL - Price-sensitive ASX Announcement
Full Release
Key Points
- Blue Star Helium Limited announced the commencement of drilling for the State 9 well (BNL) in Las Animas County, Colorado.
- The State 9 well forms part of the company’s broader drilling and exploration program targeting helium resources.
- The project is strategically significant for Blue Star’s goal to become a leading U.S. helium producer.
- The document provides an operational timeline and outlines the expected progress of drilling activities.
- Key technical, regulatory, and environmental aspects of the State 9 drilling program are addressed.
- The announcement discusses the market demand for helium and contextualizes Blue Star’s role within it.
- Forward-looking statements regarding future production potential and company strategy are included.
- Contact information for investor and media inquiries is provided.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Equatorial Resources Limited (EQX) ORDINARY FULLY PAID |
Materials |
$26 |
Update on Arbitration Against Congo
|
21 May 2025 9:12AM |
$0.140 |
$0.198 |
risen by
41.07%
|
|
| Microba Life Sciences Limited (MAP) ORDINARY FULLY PAID |
Health Care |
$44 |
MetaPanel Pathogen Study Delivers Breakthrough Results
|
21 May 2025 9:12AM |
$0.160 |
$0.072 |
fallen by
55%
|
|
MAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Microba Life Sciences Limited conducted the MetaPanel Pathogen Study to validate the MAP platform.
- MAP (Microba Advanced Pathogen Panel) leverages metagenomic sequencing for pathogen detection.
- The study showed MAP can detect a wide range of gastrointestinal pathogens, including bacteria, viruses, and parasites.
- MAP demonstrated higher sensitivity and specificity compared to traditional diagnostic methods.
- Results highlight potential for faster, more accurate clinical diagnostics using MAP.
- The technology may enable earlier intervention and improved patient care in cases of gastrointestinal illness.
- MAP's comprehensive approach is positioned to enhance public health responses to infectious disease outbreaks.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Forrestania Resources Limited (FRS) ORDINARY FULLY PAID |
Materials |
$158 |
Change in substantial holding
|
21 May 2025 9:12AM |
$0.075 |
$0.265 |
risen by
253.33%
|
|
| Whitehaven Coal Limited (WHC) ORDINARY FULLY PAID |
Energy |
$6,450 |
Update - Notification of buy-back - WHC
|
21 May 2025 9:12AM |
$5.370 |
$7.790 |
risen by
45.07%
|
|
| Infomedia Limited (IFM) ORDINARY FULLY PAID |
Information Technology |
$641 |
Response to ASX Price Query
|
21 May 2025 9:11AM |
$1.205 |
$1.695 |
risen by
40.66%
|
|
IFM - Price-sensitive ASX Announcement
Full Release
Key Points
- Infomedia Limited responded to an ASX Price Query about recent share price and trading volume movements.
- The company stated it is not aware of any unannounced information that could explain the activity.
- Infomedia confirmed compliance with ASX Listing Rules, including continuous disclosure obligations.
- There were no material changes in operations or financial circumstances to justify the fluctuations.
- The company continues to focus on its strategic priorities.
- Infomedia reaffirmed its commitment to transparent communication with shareholders and the market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hejaz High Income Active ETF (HJHI) |
Financials |
$10 |
Daily Net Asset Value (NAV) for 19.5.2025
|
21 May 2025 9:11AM |
$1.070 |
$1.110 |
risen by
3.74%
|
|
| AKORA Resources Limited (AKO) ORDINARY FULLY PAID |
Materials |
$15 |
Annual General Meeting Presentation Clarification
|
21 May 2025 9:11AM |
$0.125 |
$0.084 |
fallen by
32.80%
|
|
| Adriatic Metals Plc (ADT) ORDINARY FULLY PAID |
Materials |
- |
Statement regarding press speculation
|
21 May 2025 9:10AM |
$3.760 |
$6.220 |
risen by
65.43%
|
|
ADT - Price-sensitive ASX Announcement
Full Release
Key Points
- Adriatic Metals Plc addresses recent press speculation.
- The company is not aware of any undisclosed material information.
- No acquisition, disposal, or merger discussions are ongoing.
- Operations continue as previously reported.
- The Board is focused on existing projects and objectives.
- The company remains committed to regulatory disclosure obligations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Iltani Resources Limited (ILT) ORDINARY FULLY PAID |
Materials |
$34 |
Proposed issue of securities - ILT
|
21 May 2025 9:10AM |
$0.240 |
$0.485 |
risen by
102.08%
|
|
| Iltani Resources Limited (ILT) ORDINARY FULLY PAID |
Materials |
$34 |
Proposed issue of securities - ILT
|
21 May 2025 9:10AM |
$0.240 |
$0.485 |
risen by
102.08%
|
|
| Iltani Resources Limited (ILT) ORDINARY FULLY PAID |
Materials |
$34 |
Placement and SPP
|
21 May 2025 9:10AM |
$0.240 |
$0.485 |
risen by
102.08%
|
|
ILT - Price-sensitive ASX Announcement
Full Release
Key Points
- Iltani Resources Limited announced a $2 million Placement to institutional and sophisticated investors.
- A Share Purchase Plan (SPP) is launched to raise up to an additional $1 million from eligible shareholders.
- Both Placement and SPP shares are issued at the same price.
- Funds will primarily support exploration and drilling activities at the Herberton Project.
- Proceeds will also contribute to resource definition, further exploration, and general working capital.
- Detailed terms, pricing, eligibility, and timetable for the Placement and SPP are provided.
- The capital raising aims to strengthen Iltani’s financial position for ongoing exploration programs.
- Directors intend to participate in the Placement, subject to shareholder approval.
- The announcement includes instructions and timelines for SPP participation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$124 |
Proposed issue of securities - ILA
|
21 May 2025 9:09AM |
$0.180 |
$0.460 |
risen by
155.56%
|
|
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$124 |
Proposed issue of securities - ILA
|
21 May 2025 9:09AM |
$0.180 |
$0.460 |
risen by
155.56%
|
|
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$124 |
Proposed issue of securities - ILA
|
21 May 2025 9:08AM |
$0.180 |
$0.460 |
risen by
155.56%
|
|
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$124 |
Island completes $3.6 million placement
|
21 May 2025 9:08AM |
$0.180 |
$0.460 |
risen by
155.56%
|
|
ILA - Price-sensitive ASX Announcement
Full Release
Key Points
- Island Pharmaceuticals Limited completed a $3.6 million placement.
- Funds will support the Phase II PEACH clinical trial for ISLA-101, aimed at treating dengue fever.
- Additional proceeds to be used for further preclinical development, including Q Fever and dengue programs.
- The PEACH trial interim data is expected in the second half of 2024.
- Placement was well supported by institutional and sophisticated investors.
- The strengthened financial position enables Island to pursue milestones and advance its antiviral pipeline.
- Updates on Board and management changes are included in the announcement.
- Island focuses on vector-borne diseases and expanding its clinical and preclinical programs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.